Neuroendocrine tumors | ApexOnco - Clinical Trials news and analysis

x

“The insights provided by the analysts are great”

Andrea Gnirke-Maier

Director New Product Planning

Morphosys

Click here for more information

Trial results

21 November 2024

Perspective's lead balloon

Regulatory

29 July 2024

Bristol cuts its BCMA losses

Meanwhile, the RayzeBio-originated RYZ101 is back in Action.

Conferences Trial results

1 June 2024

ASCO 2024 – AbbVie sees SEZ6 improvement

Conferences Trial results

19 January 2024

ASCO-GI – Novartis looks for earlier Lutathera use

Deals

9 January 2024

A new kid on the radiopharma block

Deals

2 January 2024

Bristol makes its radiopharma move

The group’s $4.1bn swoop for RayzeBio follows big deals from Novartis and Lilly.

Subscribe to Neuroendocrine tumors